[4] It is not listed in any authoritative UK or EU medicines database as a licensed product
These are trial-based exclusions and do not constitute established contraindications prior to MHRA authorisation: A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Severe gastrointestinal disorders such as gastroparesis Pregnancy or breastfeeding Significant renal or hepatic impairment (pending further safety data) UK patients interested in accessing retatrutide through a clinical trial should speak with their GP or a specialist obesity service
It sends signals to your brain to reduce hunger and appetite
While GLP-1s and similar peptides famously suppress appetite, reduce blood sugar, and cause weight loss, a growing body of research suggests they might also do much more: curb inflammation all over your body, increase mitochondria in skeletal muscle to give you more energy and help you build strength, and reduce the risk of conditions ranging from Alzheimers to heart disease to alcohol use disorder
Standardized 2 mg starting dose
However, we dont yet have studies available that directly compare the two versions
